Scandinavian Real Heart AB (OSTO:HEART) EBIT: kr-35.12 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:HEART Scandinavian Real Heart AB OSTO:HEART
31 GF Score
Price kr19.90
! 4 Warning Signs
View Full Analysis

What is Scandinavian Real Heart AB EBIT?

Scandinavian Real Heart AB OSTO:HEART -2.93% 31 EBIT is kr-35.12 Mil as of Dec. 2025. GuruFocus rates OSTO:HEART with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Scandinavian Real Heart AB's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was kr-16.70 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-35.12 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Scandinavian Real Heart AB's annualized ROC % for the quarter that ended in Dec. 2025 was -55.28%. Scandinavian Real Heart AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3,732.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Scandinavian Real Heart AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -22.37%.


Scandinavian Real Heart AB  (OSTO:HEART) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Scandinavian Real Heart AB's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-34.104 * ( 1 - 0% )/( (64.23 + 59.153)/ 2 )
=-34.104/61.6915
=-55.28 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Scandinavian Real Heart AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-33.406/( ( (0.61 + max(-8.189, 0)) + (1.18 + max(-5.501, 0)) )/ 2 )
=-33.406/( ( 0.61 + 1.18 )/ 2 )
=-33.406/0.895
=-3,732.51 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (3.894 + 0 + 4.295)
=-8.189

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.239) - (2.52 + 0 + 3.22)
=-5.501

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Scandinavian Real Heart AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-35.124/156.997
=-22.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandinavian Real Heart AB EBIT Related Terms


Scandinavian Real Heart AB EBIT Historical Data

* Premium members only.

The historical data trend for Scandinavian Real Heart AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scandinavian Real Heart AB EBIT Chart

Scandinavian Real Heart AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.33 -13.85 -67.41 -33.71 -35.11

Scandinavian Real Heart AB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.55 -13.76 -19.95 -18.42 -16.70

OSTO:HEART vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Scandinavian Real Heart AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scandinavian Real Heart AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Scandinavian Real Heart AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scandinavian Real Heart AB's EV-to-EBIT falls into.


OSTO:HEART
31GF Score
Scandinavian Real Heart AB OSTO:HEART
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scandinavian Real Heart AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-35.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-35.12 Mil mean?
Scandinavian Real Heart AB (OSTO:HEART) has a EBIT of kr-35.12 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scandinavian Real Heart AB.
Is Scandinavian Real Heart AB's EBIT too high?
Scandinavian Real Heart AB's current EBIT is kr-35.12 Mil. Overall, Scandinavian Real Heart AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Scandinavian Real Heart AB's EBIT compare to ABT and SYK?
Scandinavian Real Heart AB's EBIT of kr-35.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scandinavian Real Heart AB. Scandinavian Real Heart AB's current EBIT is kr-35.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scandinavian Real Heart AB stock overvalued right now?
Scandinavian Real Heart AB (OSTO:HEART) has a current EBIT of kr-35.12 Mil. The current EBIT is kr-35.12 Mil. Scandinavian Real Heart AB's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Scandinavian Real Heart AB (OSTO:HEART), the current EBIT is kr-35.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scandinavian Real Heart AB Business Description

Other Exchanges 7820:Germany
Address Kopparbergsvagen 6, Vasteras, SWE, 722 13
Scandinavian Real Heart AB is engaged in developing an artificial heart that mimics the shape, function, and bloodflow pattern of the human heart. The company conducts research and development in medical technology and is developing an artificial heart that mimics the function of a natural heart - a so-called total artificial heart (TAH), Realhear, TAH. It is a Swedish-patented product that saves lives and improves the quality of life.
31GF Score

Get the complete analysis for OSTO:HEART

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.90
Price